Skip to main content
. 2021 Aug 1;17(8):1695–1705. doi: 10.5664/jcsm.9308

Figure 2. Treatment success rate and 5-year efficacy of mandibular advancement device therapy.

Figure 2

(A) Treatment success rate (percentage of patients with a ≥50% reduction in the AHI from baseline) during mandibular advancement device therapy in patients with OSA, overall and in patient subgroups based on baseline OSA severity (mild: AHI 5–≤15 events/h; moderate: AHI 15–≤30 events/h; severe: AHI >30 events/h). Overall: P = .0159 for the difference between 3- to 6-month FU and 2-year FU; P < .001 for the difference between 3- to 6-month FU and 5-year FU; and P = .034 for the difference between 2-year FU and 5-year FU. (B) Five-year efficacy of mandibular advancement device therapy, defined as the proportion of patients achieving an AHI of <5, <10, or < 15 events/h at 5-year follow-up, in the overall population and in patient subgroups based on baseline OSA severity (mild: AHI 5–≤15 events/h; moderate: AHI 15–≤30 events/h; severe: AHI > 30 events/h). AHI < 5 events/h: no statistically significant difference between patient subgroups; AHI < 10 events/h: P = .0015 for the difference between the mild and severe OSA subgroups and P = .0087 for the difference between the moderate and severe OSA subgroups. AHI < 15 events/h: P = .0025 for the difference between the moderate and severe OSA subgroups. AHI = apnea-hypopnea index, FU = follow-up, OSA = obstructive sleep apnea.